CALGB Institutional Grant

描述（由申请人提供）：爱荷华州大学自1986年以来一直是CALGB的成员。主要成员医院每年约有100名患者，两个附属医院约有20多名患者。在过去的5年里，我们撰写或共同主持了非小细胞肺癌、肺癌化学预防、506 U 78实验疗法和癌症恶病质中omega-3脂肪酸的研究。在行政方面，Gerald Clamon博士担任成员委员会副主席，Raymond Hohl博士担任机构绩效评估委员会（IPEC）副主席。此外，Clamon博士是呼吸委员会的成员，是癌症控制和健康结果委员会的联络员，Hohl博士是白血病委员会的成员，是药理学和实验治疗（PET）委员会的联络员，Brian Link博士是淋巴瘤委员会的成员，Badrinath Konety博士是GU委员会的成员。Nancy Rosenthal博士正在为淋巴瘤试验的血液病理学委员会审查幻灯片，Shivanand Patel博士正在为白血病委员会审查细胞遗传学，Michael Vannier博士正在为一个新的委员会服务，以评估肿瘤成像的新技术。爱荷华州大学新的转化研究导致了两种新的有前途的抗癌疗法的发展。在爱荷华州大学的乔治韦纳博士的实验室开发的HU 1D 10抗体已经在爱荷华州大学完成了I期试验，并证明了对淋巴瘤的活性。在爱荷华州大学实验室开发的CpG寡脱氧核苷酸或亚瑟Krieg博士现在正在爱荷华州大学完成I期试验。Pneumovax加GM-CSF的试点研究正在爱荷华州大学完成。这将导致CALGB的III期试验，并可能提高免疫抑制癌症患者接种疫苗的成功率。

DESCRIPTION (provided by applicant): The University of Iowa has been a member of CALGB since 1986. Accrual at the main member hospital is approximately 100 patients per year and approximately 20 more patients are accrued at two affiliates. Over the past 5 years, we have authored or co-chaired studies in non-small cell lung cancer, in chemoprevention of lung cancer, in experimental therapeutics for 506U78, and for omega-3 fatty acids in cancer cachexia. Administratively, Dr. Gerald Clamon has been vice chair of the Membership Committee and Dr. Raymond Hohl has been vice chair of the Institutional Performance Evaluation Committee (IPEC). In addition, Dr. Clamon is on the Respiratory Committee and is the liaison to the Cancer Control and Health Outcomes Committee, Dr. Hohl is on the Leukemia Committee and is the liaison to the Pharmacology and Experimental Therapeutics (PET) Committee, Dr. Brian Link is on the Lymphoma Committee, and Dr. Badrinath Konety is on the GU Committee. Dr. Nancy Rosenthal is reviewing slides for the Hematopathology Committee for a lymphoma trial, Dr. Shivanand Patel reviews cytogenetics for the Leukemia Committee, and Dr. Michael Vannier is serving on a new committee to evaluate new technologies in the imaging of tumors. New translational research at the University of Iowa has lead to the development of two new promising anti-cancer therapies. The HU 1D10 antibody developed in the laboratory of Dr. George Weiner at the University of Iowa has completed Phase I trials at the University of Iowa and demonstrated activity against lymphoma. The CpG oligodeoxynucleotide developed at the University of Iowa in the lab or Dr. Arthur Krieg is now completing Phase I trials at the University of Iowa. A pilot study of Pneumovax plus GM-CSF is being completed at the University of Iowa. This should lead to a phase III trial within CALGB and potentially improve success with vaccinations of the immune suppressed cancer patient.